NO20042779L - Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger - Google Patents

Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Info

Publication number
NO20042779L
NO20042779L NO20042779A NO20042779A NO20042779L NO 20042779 L NO20042779 L NO 20042779L NO 20042779 A NO20042779 A NO 20042779A NO 20042779 A NO20042779 A NO 20042779A NO 20042779 L NO20042779 L NO 20042779L
Authority
NO
Norway
Prior art keywords
agonist
partial
pharmaceutical compositions
containing pharmaceutical
compositions
Prior art date
Application number
NO20042779A
Other languages
English (en)
Norwegian (no)
Inventor
Jerome Aubert
Vitzing Christian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042779L publication Critical patent/NO20042779L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042779A 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger NO20042779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (de) 2001-12-21 2001-12-21 Feste orale Zubereitung mit Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20042779L true NO20042779L (no) 2004-09-17

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042779A NO20042779L (no) 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Country Status (31)

Country Link
US (2) US20050106236A1 (de)
EP (2) EP1321142A1 (de)
JP (1) JP4718776B2 (de)
KR (1) KR100980144B1 (de)
CN (1) CN100464749C (de)
AR (1) AR037937A1 (de)
AT (1) ATE320807T1 (de)
AU (1) AU2002361198B2 (de)
BR (1) BR0215148A (de)
CA (1) CA2470668C (de)
CO (1) CO5640102A2 (de)
CY (1) CY1105559T1 (de)
DE (1) DE60210139T2 (de)
DK (1) DK1458377T3 (de)
EC (1) ECSP105163A (de)
EG (1) EG24194A (de)
ES (1) ES2258171T3 (de)
HU (1) HU226589B1 (de)
IL (2) IL162451A0 (de)
MX (1) MXPA04006157A (de)
MY (1) MY139546A (de)
NO (1) NO20042779L (de)
NZ (1) NZ533585A (de)
PE (1) PE20030872A1 (de)
PL (1) PL369509A1 (de)
PT (1) PT1458377E (de)
RU (1) RU2322978C2 (de)
SI (1) SI1458377T1 (de)
TW (1) TWI260221B (de)
WO (1) WO2003053432A1 (de)
ZA (1) ZA200404467B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (de) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
PT3395338T (pt) 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
PT1200090E (pt) * 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.

Also Published As

Publication number Publication date
SI1458377T1 (sl) 2006-08-31
MXPA04006157A (es) 2004-10-27
ATE320807T1 (de) 2006-04-15
MY139546A (en) 2009-10-30
CA2470668A1 (en) 2003-07-03
RU2004122631A (ru) 2005-08-10
IL162451A (en) 2009-02-11
US20090104263A1 (en) 2009-04-23
CO5640102A2 (es) 2006-05-31
EP1321142A1 (de) 2003-06-25
RU2322978C2 (ru) 2008-04-27
ECSP105163A (es) 2010-07-30
HU226589B1 (en) 2009-04-28
TWI260221B (en) 2006-08-21
CN100464749C (zh) 2009-03-04
CY1105559T1 (el) 2010-07-28
ES2258171T3 (es) 2006-08-16
CN1606438A (zh) 2005-04-13
PE20030872A1 (es) 2003-11-24
AU2002361198B2 (en) 2006-06-08
DE60210139D1 (de) 2006-05-11
TW200410684A (en) 2004-07-01
KR20040066922A (ko) 2004-07-27
DE60210139T2 (de) 2006-08-17
EG24194A (en) 2008-10-14
AR037937A1 (es) 2004-12-22
CA2470668C (en) 2011-07-05
HUP0402492A3 (en) 2008-04-28
BR0215148A (pt) 2004-10-19
EP1458377A1 (de) 2004-09-22
WO2003053432A1 (en) 2003-07-03
AU2002361198A1 (en) 2003-07-09
ZA200404467B (en) 2006-05-31
HUP0402492A2 (hu) 2005-07-28
DK1458377T3 (da) 2006-06-12
IL162451A0 (en) 2005-11-20
PL369509A1 (en) 2005-04-18
US20050106236A1 (en) 2005-05-19
JP4718776B2 (ja) 2011-07-06
PT1458377E (pt) 2006-07-31
NZ533585A (en) 2006-04-28
KR100980144B1 (ko) 2010-09-03
EP1458377B1 (de) 2006-03-22
JP2005516946A (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
NO20042779L (no) Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger
FI20011478A0 (fi) Farmaseuttinen koostumus
FI20010780A0 (fi) Parannetut koostumukset
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20001749A0 (fi) Farmaseuttisia koostumuksia
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE200300416A (et) Ravimvorm
ITMI20010748A0 (it) Composizioni farmaceutiche
EE200300589A (et) Ravimkoostised
IS7081A (is) Lyfjablanda
FI20022128A0 (fi) Farmaseuttinen koostumus
EP1461096A4 (de) Rotierender kompressor
NO20031095L (no) Farmasoytiske sammensetninger
GB0104752D0 (en) Pharmaceutical compositions
ITTO20020744A0 (it) Composizione
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
DE60140529D1 (de) Feuerlöschende Zusammensetzung
ITTO20020745A0 (it) Composizione
EE200200689A (et) Ravimkoostised
NO20015694D0 (no) Emballasje
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
SE0103116D0 (sv) Pharmaceutical combination
FIU20010427U0 (fi) Jippopakkaus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application